GH Replacement Improves Quality of Life and Metabolic Parameters in Cured Acromegalic Patients with Growth Hormone Deficiency
Open Access
- 1 November 2012
- journal article
- other
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 97 (11) , 3983-3988
Abstract
Objective: Effects of GH replacement in patients with GH deficiency (GHD) after a cure for acromegaly so far have been poorly studied, although its prevalence among acromegalic patients may reach the 60%. The aim of the study was to evaluate whether metabolic parameters and quality of life are improved by GH replacement in patients with prior acromegaly and severe GHD. Design and Methods: This was a prospective study on 42 GHD subjects [22 men, mean age (sd): 48 ± 10]: 10 acromegalics treated with recombinant human GH (group A), 12 acromegalics who refused treatment (group B), and 20 subjects operated for nonfunctioning pituitary adenoma on recombinant human GH (group C). Serum IGF-I levels, lipid profile, glucose levels (fasting and after an oral glucose tolerance test), glycosylated hemoglobin, insulin resistance (homeostasis model assessment insulin resistance index), anthropometric parameters (body mass index, waist circumference, body composition), and quality of life (Questions on Life Satisfaction-Hypopituitarism Z-scores) were evaluated at baseline and after 12 and 36 months. Results: At baseline, group B showed higher IGF sd score than group A and C, as well as better quality of life and higher post-oral glucose tolerance test glucose levels than group A. After 12-months, similarly in group A and C, the IGF-I sd score significantly increased, and body composition and lipid profile improved, without deterioration of glucose tolerance. Quality of life significantly improved too, and the baseline difference between group A and B disappeared. Results were confirmed after 36 months. Conclusions: In GHD acromegalic patients, GH therapy improved body composition, lipid profile, and quality of life as in patients with GHD due to nonfunctioning pituitary adenoma, without negative effects on glucose metabolism. GH replacement therapy should be considered in these patients, as in patients with GHD from other causes.Keywords
This publication has 21 references indexed in Scilit:
- Predictors of morbidity and mortality in acromegaly: an Italian surveyEuropean Journal of Endocrinology, 2012
- Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegalyClinical Endocrinology, 2012
- The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegalyClinical Endocrinology, 2011
- Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2011
- Prevalence of GH deficiency in cured acromegalic patients: impact of different previous treatmentsEuropean Journal of Endocrinology, 2009
- Baseline Characteristics and the Effects of Two Years of Growth Hormone (GH) Replacement Therapy in Adults with GH Deficiency Previously Treated for AcromegalyThe Journal of Clinical Endocrinology & Metabolism, 2008
- Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's diseaseEuropean Journal of Endocrinology, 2002
- Optimizing Growth Hormone Replacement Therapy by Dose Titration in Hypopituitary AdultsThe Journal of Clinical Endocrinology & Metabolism, 1998
- Clinical aspects of growth hormone deficiency in adultsEndocrine Reviews, 1995
- The Effects of Treatment with Recombinant Human Growth Hormone on Body Composition and Metabolism in Adults with Growth Hormone DeficiencyNew England Journal of Medicine, 1989